A Blueprint Medicines Corp. patent describes new cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Title: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4/6 inhibitor resistant ER+/HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation ...

04, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and ...

In September, Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz ®) and initial data from the Phase 1 ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

2020). CDK2 inhibitors: Indisulam (E7070) is a type of CDK2 inhibitor that inhibits the activation of cyclinE–CDK2 and the cell cycle, causing G1/S arrest. Ziva Pogacar et al. reported that indisulam ...